Health knowledge made personal
Join this community!
› Share page:
Search posts:

Drug Combination of DNA Topoisomerase I (TOP1) Inhibitors and Extracellular ATP Produces a Significant Increase in Beneficial An

Posted Oct 20 2010 8:00pm

Description of Invention:
DNA topoisomerase inhibitors are a category of drugs used for cancer therapy. DNA topoisomerase 1 (TOP1) inhibitors, such as Camptothecin (CPT) and its structurally related analogues, bind to the TOP1 complex and prevent the religation of the single strand DNA molecules, ultimately leading to cell death. CPT and close analogues show anticancer activity in clinical trials treating ovarian, small-cell lung, and colorectal cancers, but also adverse drug reaction. By reducing the cytotoxic dose in the thousands of folds, the NIH scientists are able to target the tumor and reduce the cytotoxicity to normal cells. The instant invention discloses that the drug combination of DNA topoisomerase 1 (TOP1) inhibitors, such as the anti-cancer drug Camptothecin (CPT), and extracellular ATP produces a significant increase in beneficial anti-carcinoma cytotoxicity.

This invention may provide a new combination of drug with extracellular ATP to target various cancers for treatment.

Development Status:
Pre-clinical stage of development

Joseph Riss (NCI)
Glenn Y Merlino (NCI)
J. Carl Barrett (Novartis Institutes for BioMedical Research, Inc.)

Patent Status:
HHS, Reference No. E-098-2010/0
US, Application No. 61/350,660 filed 02 Jun 2010

Relevant Publication:
  1. Manuscript in preparation.

Licensing Status:
Available for licensing

Cancer - Therapeutics

For Licensing Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-594-6565
Fax: 301-402-0220

Ref No: 2177

Updated: 10/2010

Post a comment
Write a comment:

Related Searches